Horizon Europe’s 2026–2027 work programme combines broad health research opportunities with changes to applications and new support for taking existing results further.
ERDERA’s third General Assembly brought partners together in Coimbra to review its second year, strengthen connections across the partnership and align priorities for a more integrated and delivery-focused third year.
ERDERA marked the close of its second year with an Open Session on ultra-rare diseases, bringing together European, regulatory and scientific perspectives on how innovation can reach patients.
The assessment compares diagnosis, treatment access and national governance across 16 countries, examining gaps in rare disease support throughout the life course.
The document outlines the Call's 2027 proposed research scope, eligibility criteria, consortium requirements and preliminary application timetable for multinational collaborations on recently identified rare diseases.
ERDERA will return to the World Orphan Drug Congress Europe with a booth and an interactive pre-conference workshop examining where artificial intelligence can support rare disease research and therapeutic development, and where human expertise remains essential.
